NEW YORK – Enzo Biochem reported after the close of the market on Thursday that revenues for its fiscal second quarter ticked up less than 1 percent year over year, as the Protecting Access to Medicare Act (PAMA) continued to negatively affect reimbursements from Medicare and third-party payers.
For the three months ended Jan. 31, the diagnostics company reported total revenues of $19.4 million, compared to $19.3 million in the year-ago quarter.